Evidence mapPaperPMID 42380410Full record

ArticleEJNMMI radiopharmacy and chemistry2026

High-yield, standardised automated radiosynthesis process for routine clinical insulinoma PET with [⁶⁸Ga]Ga-NODAGA-exendin-4.

Elodie Duray, Matthieu Sacrez, Marine Hawotte, Charlotte Collet, Christian Vanasschen, Nicolas Veran, Corentin Warnier

Abstract read
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Elodie Duraydépartement de Recherche et Développement, Trasis SA, Ans, Belgium. duray.elodie@gmail.com.ORCID http://orcid.org/0009-0005-6127-7702
Matthieu SacrezCHRU, Strasbourg, France.
Marine Hawottedépartement de Recherche et Développement, Trasis SA, Ans, Belgium.
Charlotte ColletUniversité de Lorraine, Inserm, IADI, Nancy, France.
Christian Vanasschendépartement de Recherche et Développement, Trasis SA, Ans, Belgium.
Nicolas VeranCHRU, Nancy, France.
Corentin Warnierdépartement de Recherche et Développement, Trasis SA, Ans, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInsulinoma is a rare pancreatic neuroendocrine tumour characterised by inappropriate insulin secretion and recurrent hypoglycaemia. Owing to their small size and intrapancreatic localisation, insulinomas are frequently difficult to detect using conventional anatomical imaging techniques. Functional imaging based on positron emission tomography has therefore gained increasing interest, particularly through targeting of the glucagon-like peptide-1 receptor, which is highly overexpressed in most insulinomas. Among available tracers, gallium-68-labelled NODAGA-exendin-4 has demonstrated excellent diagnostic performance. However, its routine clinical implementation remains limited by the absence of a harmonised, robust and transferable radiosynthesis protocol compatible with hospital radiopharmacy practice. The aim of this work was to optimise and harmonise the automated preparation of gallium-68-labelled NODAGA-exendin-4 by systematically evaluating critical synthesis parameters and validating the optimised process across multiple commercially available gallium-68 generators. Using an automated synthesis module, key variables including precursor amount, labelling temperature and duration, formulation additives, workflow sequence and quality control conditions were investigated. The optimised protocol was subsequently validated using generators from three different manufacturers.

resultsOptimisation studies demonstrated that formulation-related parameters, particularly the post-labelling addition of polysorbate 20, resulted in improved radiochemical conversion and reduced residual activity within the synthesis cassette. An optimal precursor amount of 20 µg was identified as a compromise between radiochemical yield and clinical injectability constraints. Radiolabelling at 95 °C for 12 min ensured high conversion while reducing overall synthesis time. Validation runs showed excellent reproducibility, with non-decay-corrected yields ranging from 60 to 73% and decay-corrected yields reaching up to 93%, independent of generator type. Radiochemical purity consistently exceeded 95%, and all quality control parameters complied with established specifications.

conclusionsThis study establishes a simplified, efficient and generator-independent automated synthesis of gallium-68-labelled NODAGA-exendin-4. By addressing key translational and regulatory constraints, the proposed protocol provides a practical foundation for the routine clinical implementation of glucagon-like peptide-1 receptor imaging in patients with suspected insulinoma.

Indexed as

AutomationGallium-68GLP-1NODAGA-exendin-4PETRadiosynthesis

Identifiers

PMID42380410
PMCPMC13373115

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.